Document is current

Any future updates will be listed below

Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman’s disease

Crossref DOI link: https://doi.org/10.1007/s00277-015-2353-8

Published Online: 2015-03-21

Published Print: 2015-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark